• Something wrong with this record ?

Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis

TC. Assumpção, DM. Mizurini, D. Ma, RQ. Monteiro, S. Ahlstedt, M. Reyes, M. Kotsyfakis, TN. Mather, JF. Andersen, J. Lukszo, JMC. Ribeiro, IMB. Francischetti,

. 2018 ; 8 (1) : 4806. [pub] 20180319

Language English Country Great Britain

Document type Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't

Grant support
ZIA AI000810 NIAID NIH HHS - United States

Tick saliva is a rich source of modulators of vascular biology. We have characterized Ixonnexin, a member of the "Basic-tail" family of salivary proteins from the tick Ixodes scapularis. Ixonnexin is a 104 residues (11.8 KDa), non-enzymatic basic protein which contains 3 disulfide bonds and a C-terminal rich in lysine. It is homologous to SALP14, a tick salivary FXa anticoagulant. Ixonnexin was produced by ligation of synthesized fragments (51-104) and (1-50) followed by folding. Ixonnexin, like SALP14, interacts with FXa. Notably, Ixonnexin also modulates fibrinolysis in vitro by a unique salivary mechanism. Accordingly, it accelerates plasminogen activation by tissue-type plasminogen activator (t-PA) with Km 100 nM; however, it does not affect urokinase-mediated fibrinolysis. Additionally, lysine analogue ε-aminocaproic acid inhibits Ixonnexin-mediated plasmin generation implying that lysine-binding sites of Kringle domain(s) of plasminogen or t-PA are involved in this process. Moreover, surface plasmon resonance experiments shows that Ixonnexin binds t-PA, and plasminogen (KD 10 nM), but not urokinase. These results imply that Ixonnexin promotes fibrinolysis by supporting the interaction of plasminogen with t-PA through formation of an enzymatically productive ternary complex. Finally, in vivo experiments demonstrates that Ixonnexin inhibits FeCl3-induced thrombosis in mice. Ixonnexin emerges as novel modulator of fibrinolysis which may also affect parasite-vector-host interactions.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045525
003      
CZ-PrNML
005      
20200113082330.0
007      
ta
008      
200109s2018 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-018-22780-1 $2 doi
035    __
$a (PubMed)29555911
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Assumpção, Teresa C $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
245    10
$a Ixonnexin from Tick Saliva Promotes Fibrinolysis by Interacting with Plasminogen and Tissue-Type Plasminogen Activator, and Prevents Arterial Thrombosis / $c TC. Assumpção, DM. Mizurini, D. Ma, RQ. Monteiro, S. Ahlstedt, M. Reyes, M. Kotsyfakis, TN. Mather, JF. Andersen, J. Lukszo, JMC. Ribeiro, IMB. Francischetti,
520    9_
$a Tick saliva is a rich source of modulators of vascular biology. We have characterized Ixonnexin, a member of the "Basic-tail" family of salivary proteins from the tick Ixodes scapularis. Ixonnexin is a 104 residues (11.8 KDa), non-enzymatic basic protein which contains 3 disulfide bonds and a C-terminal rich in lysine. It is homologous to SALP14, a tick salivary FXa anticoagulant. Ixonnexin was produced by ligation of synthesized fragments (51-104) and (1-50) followed by folding. Ixonnexin, like SALP14, interacts with FXa. Notably, Ixonnexin also modulates fibrinolysis in vitro by a unique salivary mechanism. Accordingly, it accelerates plasminogen activation by tissue-type plasminogen activator (t-PA) with Km 100 nM; however, it does not affect urokinase-mediated fibrinolysis. Additionally, lysine analogue ε-aminocaproic acid inhibits Ixonnexin-mediated plasmin generation implying that lysine-binding sites of Kringle domain(s) of plasminogen or t-PA are involved in this process. Moreover, surface plasmon resonance experiments shows that Ixonnexin binds t-PA, and plasminogen (KD 10 nM), but not urokinase. These results imply that Ixonnexin promotes fibrinolysis by supporting the interaction of plasminogen with t-PA through formation of an enzymatically productive ternary complex. Finally, in vivo experiments demonstrates that Ixonnexin inhibits FeCl3-induced thrombosis in mice. Ixonnexin emerges as novel modulator of fibrinolysis which may also affect parasite-vector-host interactions.
650    _2
$a zvířata $7 D000818
650    _2
$a arteriální okluzní nemoci $x chemicky indukované $x patologie $x prevence a kontrola $7 D001157
650    _2
$a chloridy $x toxicita $7 D002712
650    _2
$a železité sloučeniny $x toxicita $7 D005290
650    _2
$a fibrinolýza $x účinky léků $7 D005342
650    _2
$a myši $7 D051379
650    _2
$a noxy $x toxicita $7 D009676
650    _2
$a plazminogen $x metabolismus $7 D010958
650    _2
$a sliny $x metabolismus $7 D012463
650    _2
$a slinné proteiny a peptidy $x farmakologie $7 D012471
650    _2
$a trombóza $x chemicky indukované $x patologie $x prevence a kontrola $7 D013927
650    _2
$a klíšťata $x metabolismus $7 D013987
650    _2
$a tkáňový aktivátor plazminogenu $x metabolismus $7 D010959
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Intramural $7 D052060
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mizurini, Daniella M $u Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
700    1_
$a Ma, Dongying $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
700    1_
$a Monteiro, Robson Q $u Institute of Medical Biochemistry, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
700    1_
$a Ahlstedt, Sydney $u Department of Pathology, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
700    1_
$a Reyes, Morayma $u Department of Pathology, Albert Einstein College of Medicine & Montefiore Medical Center, Bronx, NY, USA.
700    1_
$a Kotsyfakis, Michail $u Institute of Parasitology, Biology Center, Czech Academy of Sciences, České Budějovice, Czech Republic.
700    1_
$a Mather, Thomas N $u Rhode Island Center for Vector-Borne Disease, University of Rhode Island, Kingston, Rhode Island, USA.
700    1_
$a Andersen, John F $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
700    1_
$a Lukszo, Jan $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
700    1_
$a Ribeiro, José M C $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA.
700    1_
$a Francischetti, Ivo M B $u Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, USA. ivofrancischetti@gmail.com.
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 8, č. 1 (2018), s. 4806
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29555911 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113082702 $b ABA008
999    __
$a ok $b bmc $g 1483793 $s 1084198
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 8 $c 1 $d 4806 $e 20180319 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a ZIA AI000810 $p NIAID NIH HHS $2 United States
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...